Disc Medicine, Inc. (NASDAQ:IRON) CEO Sells $844,333.91 in Stock

Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) CEO John D. Quisel sold 12,791 shares of the stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $66.01, for a total transaction of $844,333.91. Following the completion of the sale, the chief executive officer now owns 72,065 shares of the company's stock, valued at approximately $4,757,010.65. The trade was a 15.07 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Disc Medicine Trading Down 2.3 %

IRON traded down $1.50 on Wednesday, hitting $63.50. The company had a trading volume of 327,848 shares, compared to its average volume of 347,116. Disc Medicine, Inc. has a 1 year low of $25.60 and a 1 year high of $77.60. The firm has a market cap of $1.89 billion, a P/E ratio of -15.95 and a beta of 0.76. The company's fifty day moving average price is $58.19 and its 200 day moving average price is $50.24.

Disc Medicine (NASDAQ:IRON - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.89) EPS for the quarter, topping the consensus estimate of ($1.04) by $0.15. On average, analysts predict that Disc Medicine, Inc. will post -4.05 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the company. Scotiabank upped their price target on Disc Medicine from $62.00 to $70.00 and gave the company a "sector outperform" rating in a research report on Tuesday, November 5th. Cantor Fitzgerald restated an "overweight" rating and issued a $85.00 target price on shares of Disc Medicine in a report on Tuesday, October 15th. Morgan Stanley upgraded Disc Medicine from an "equal weight" rating to an "overweight" rating and set a $85.00 price target on the stock in a report on Tuesday, November 5th. Jefferies Financial Group began coverage on shares of Disc Medicine in a research report on Wednesday, October 23rd. They set a "buy" rating and a $89.00 price target on the stock. Finally, Stifel Nicolaus raised their price objective on shares of Disc Medicine from $79.00 to $90.00 and gave the stock a "buy" rating in a research report on Tuesday, December 10th. Nine investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $87.50.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Exome Asset Management LLC increased its stake in Disc Medicine by 5.8% during the third quarter. Exome Asset Management LLC now owns 64,516 shares of the company's stock worth $3,170,000 after purchasing an additional 3,516 shares during the period. Teachers Retirement System of The State of Kentucky grew its holdings in shares of Disc Medicine by 38.7% in the third quarter. Teachers Retirement System of The State of Kentucky now owns 19,560 shares of the company's stock valued at $961,000 after purchasing an additional 5,458 shares in the last quarter. Geode Capital Management LLC increased its stake in Disc Medicine by 17.6% during the 3rd quarter. Geode Capital Management LLC now owns 474,719 shares of the company's stock worth $23,333,000 after buying an additional 70,983 shares during the period. Barclays PLC lifted its holdings in Disc Medicine by 123.7% during the 3rd quarter. Barclays PLC now owns 40,145 shares of the company's stock worth $1,972,000 after buying an additional 22,202 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd purchased a new position in Disc Medicine in the 3rd quarter valued at approximately $445,000. 83.70% of the stock is currently owned by institutional investors and hedge funds.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.